WO2022226812A1 - 一种使用手性辅基制备左旋特布他林的方法 - Google Patents
一种使用手性辅基制备左旋特布他林的方法 Download PDFInfo
- Publication number
- WO2022226812A1 WO2022226812A1 PCT/CN2021/090369 CN2021090369W WO2022226812A1 WO 2022226812 A1 WO2022226812 A1 WO 2022226812A1 CN 2021090369 W CN2021090369 W CN 2021090369W WO 2022226812 A1 WO2022226812 A1 WO 2022226812A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- terbutaline
- added
- preparing
- tert
- Prior art date
Links
- 229960000195 terbutaline Drugs 0.000 title claims abstract description 33
- 238000000034 method Methods 0.000 title claims abstract description 25
- 150000001875 compounds Chemical class 0.000 claims abstract description 49
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims abstract description 36
- 239000002904 solvent Substances 0.000 claims abstract description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 27
- 229940125898 compound 5 Drugs 0.000 claims abstract description 21
- CESUXLKAADQNTB-UHFFFAOYSA-N tert-butanesulfinamide Chemical compound CC(C)(C)S(N)=O CESUXLKAADQNTB-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000003054 catalyst Substances 0.000 claims abstract description 19
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims abstract description 16
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- RKSOPLXZQNSWAS-UHFFFAOYSA-N tert-butyl bromide Chemical compound CC(C)(C)Br RKSOPLXZQNSWAS-UHFFFAOYSA-N 0.000 claims abstract description 10
- 238000006722 reduction reaction Methods 0.000 claims abstract description 9
- 229910052763 palladium Inorganic materials 0.000 claims abstract description 8
- -1 tert-butylsulfinyl group Chemical group 0.000 claims abstract description 6
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims abstract description 5
- 238000006555 catalytic reaction Methods 0.000 claims abstract description 4
- 239000002994 raw material Substances 0.000 claims abstract description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 51
- 238000006243 chemical reaction Methods 0.000 claims description 34
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical group C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 claims description 16
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 8
- 239000012279 sodium borohydride Substances 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 4
- 239000003513 alkali Substances 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 30
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- 239000007787 solid Substances 0.000 description 23
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 20
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 18
- 238000001914 filtration Methods 0.000 description 11
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 10
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 229910052938 sodium sulfate Inorganic materials 0.000 description 10
- 235000011152 sodium sulphate Nutrition 0.000 description 10
- 229910000027 potassium carbonate Inorganic materials 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 8
- 239000001257 hydrogen Substances 0.000 description 8
- 238000007327 hydrogenolysis reaction Methods 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 7
- 239000012046 mixed solvent Substances 0.000 description 7
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 239000012047 saturated solution Substances 0.000 description 6
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 6
- 235000019270 ammonium chloride Nutrition 0.000 description 5
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 5
- 150000002576 ketones Chemical class 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 235000017557 sodium bicarbonate Nutrition 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 238000005292 vacuum distillation Methods 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- UORVGPXVDQYIDP-UHFFFAOYSA-N borane Chemical compound B UORVGPXVDQYIDP-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 description 2
- 229910000085 borane Inorganic materials 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- NROKBHXJSPEDAR-UHFFFAOYSA-M potassium fluoride Chemical compound [F-].[K+] NROKBHXJSPEDAR-UHFFFAOYSA-M 0.000 description 2
- 150000003333 secondary alcohols Chemical class 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- WYECURVXVYPVAT-UHFFFAOYSA-N 1-(4-bromophenyl)ethanone Chemical compound CC(=O)C1=CC=C(Br)C=C1 WYECURVXVYPVAT-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- SPNQRCTZKIBOAX-UHFFFAOYSA-N Butralin Chemical compound CCC(C)NC1=C([N+]([O-])=O)C=C(C(C)(C)C)C=C1[N+]([O-])=O SPNQRCTZKIBOAX-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 235000000385 Costus speciosus Nutrition 0.000 description 1
- 244000258136 Costus speciosus Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 102000006463 Talin Human genes 0.000 description 1
- 108010083809 Talin Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- RYQWRJXJEBRCFI-UHFFFAOYSA-M azanium tetrabutylazanium dibromide Chemical compound [Br-].C(CCC)[N+](CCCC)(CCCC)CCCC.[Br-].[NH4+] RYQWRJXJEBRCFI-UHFFFAOYSA-M 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- CHQVQXZFZHACQQ-UHFFFAOYSA-M benzyl(triethyl)azanium;bromide Chemical compound [Br-].CC[N+](CC)(CC)CC1=CC=CC=C1 CHQVQXZFZHACQQ-UHFFFAOYSA-M 0.000 description 1
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 description 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 1
- 102000015005 beta-adrenergic receptor activity proteins Human genes 0.000 description 1
- 108040006818 beta-adrenergic receptor activity proteins Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- REJPDMLLCDXIOV-UHFFFAOYSA-N but-2-ynal Chemical compound CC#CC=O REJPDMLLCDXIOV-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012004 corey–bakshi–shibata catalyst Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000000420 mucociliary effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- LIGACIXOYTUXAW-UHFFFAOYSA-N phenacyl bromide Chemical compound BrCC(=O)C1=CC=CC=C1 LIGACIXOYTUXAW-UHFFFAOYSA-N 0.000 description 1
- IMACFCSSMIZSPP-UHFFFAOYSA-N phenacyl chloride Chemical compound ClCC(=O)C1=CC=CC=C1 IMACFCSSMIZSPP-UHFFFAOYSA-N 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011698 potassium fluoride Substances 0.000 description 1
- 235000003270 potassium fluoride Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 239000010970 precious metal Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 150000003892 tartrate salts Chemical class 0.000 description 1
- HWCKGOZZJDHMNC-UHFFFAOYSA-M tetraethylammonium bromide Chemical compound [Br-].CC[N+](CC)(CC)CC HWCKGOZZJDHMNC-UHFFFAOYSA-M 0.000 description 1
- BGQMOFGZRJUORO-UHFFFAOYSA-M tetrapropylammonium bromide Chemical compound [Br-].CCC[N+](CCC)(CCC)CCC BGQMOFGZRJUORO-UHFFFAOYSA-M 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000009901 transfer hydrogenation reaction Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/20—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated the carbon skeleton being saturated and containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/08—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/64—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms
- C07C217/66—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain
- C07C217/70—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains further substituted by singly-bound oxygen atoms with singly-bound oxygen atoms and six-membered aromatic rings bound to the same carbon atom of the carbon chain linked by carbon chains having two carbon atoms between the amino groups and the six-membered aromatic ring or the condensed ring system containing that ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C313/02—Sulfinic acids; Derivatives thereof
- C07C313/06—Sulfinamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/09—Geometrical isomers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the invention belongs to the technical field of medicine, and in particular relates to a chiral preparation method of levterbutaline.
- Terbutaline is a fast-acting and short-acting ⁇ -adrenoceptor agonist, which can selectively activate ⁇ 2 receptors, relax bronchial smooth muscle, inhibit the release of endogenous spasmolytics and inhibit the release of endogenous transmitters and Edema due to increased mucociliary clearance (Kyeong HK, Hyun JK, Seon-Pyo H., Sang DS, Arch. Pharm. Res. 2000, 23:441-445). Clinically, it is mainly used to treat bronchial asthma, asthmatic bronchitis, emphysema and bronchospasm in chronic obstructive pulmonary disease.
- Terbutaline has a chiral center of a benzylic secondary alcohol, but the racemates are currently used clinically.
- the levorotatory body of terbutaline is the active ingredient that exerts its efficacy ( J. Med. Chem. , 1972, 15 , 1182-1183 ), and the dextrorotate body is not only ineffective, but also has toxic and side effects, so the study of levorotatory
- the preparation method of butaline, and the re-marketing of this levorotatory form has important clinical application value.
- CN110156614A disclosed that compared with the commercially available racemate, levorotatory ( ⁇ ) terbutaline can double the anti-bacterial effect. Asthma efficacy, providing a new preferred treatment plan for asthma-related diseases.
- the published preparation methods of L-terbutaline mainly include the following: 1. Splitting method.
- the use of tartaric acid or tartaric acid derivatives to split racemic terbutaline is the most simple and intuitive method for preparing lev-terbutaline (CN1273966A, CN201810147612.1).
- this method often requires multiple crystallizations to obtain satisfactory enantiomeric purity.
- the whole process is complicated to operate, the yield is low, and at least half of the products are discarded, which does not conform to the principles of green chemistry currently advocated.
- the enzymatic reduction method is a common method for preparing chiral secondary alcohols from latent chiral ketones, but it needs to screen suitable enzyme catalysts and often has disadvantages such as low reduction efficiency (Journal). of Molecular Catalysis B: Enzymatic, 84, (2012), 83–88).
- chiral ruthenium-catalyzed transfer hydrogenation method achieves asymmetric reduction of 2-chloroacetophenone, and obtains a key intermediate for the synthesis of L-terbutaline (Chem. Pharm. Bull. 65, (2017), 389-395).
- This kind of method uses expensive precious metals, and the ee of the product is only 91%, which cannot meet the demand.
- the purpose of the present invention is to provide a method for preparing levoterbutaline; the method is simple and reliable, the preparation cost is low, and the ee of the chiral product is as high as 99.9%.
- the technical scheme of the present invention is: a method for preparing L-terbutaline by using a chiral prosthetic group, in the presence of a palladium catalyst and hydrochloric acid, hydrogenolysis of compound 7 in an alcohol solvent is performed to obtain L-terbutaline; wherein,
- the chemical structural formula of compound 7 is as follows.
- the palladium catalyst is a palladium-carbon catalyst
- the alcohol solvent is a small molecular alcohol, preferably methanol.
- compound 7 was dissolved in methanol, palladium-carbon catalyst was added, hydrochloric acid was added dropwise, hydrogenolysis was carried out in normal pressure hydrogen for 1 to 3 hours, palladium-carbon was removed by filtration, the filtrate was distilled under reduced pressure, and the residual solid was crystallized to obtain the product hydrochloric acid Levoterbutaline 8 .
- Ketones are reduced to chiral alcohols (compound 6 ) under the control of chiral tert-butyl sulfinamide.
- Compound 5 was dissolved in a solvent, quaternary ammonium salt was added, and sodium borohydride was added in batches within 1 to 2 hours at 0 to 10 °C.
- the organic solvent refers to one or more of THF, ethanol, methanol, and isopropanol, preferably a mixed solvent of THF and isopropanol;
- Described quaternary ammonium salt refers to tetrabutylammonium bromide, tetrabutylammonium chloride, tetrapropylammonium bromide, tetraethylammonium bromide or triethylbenzylammonium bromide, preferably tetrabutylammonium bromide ammonium and tetrabutylammonium chloride, more preferably tetrabutylammonium bromide; the reaction is shown below.
- the present invention has the following advantages compared with the prior art: the present invention uses the commercialized cheap chiral source tert-butyl sulfinamide as the auxiliary group for the first time to control the asymmetric reduction of the ketone, and a small amount of non- The enantiomers are easily removed by crystallization, and the ee of the product is as high as 99.9%; the operation of the whole route is very simple, and the reagents used are cheap, readily available, non-toxic, and very suitable for industrial production.
- Fig. 1 is the hydrogen nuclear magnetic spectrum of the hydrochloride of R-terbutaline prepared in Example 1.
- Fig. 2 is the carbon nuclear magnetic spectrum of the hydrochloride of R-terbutaline prepared in Example 1.
- Figure 3 is the mass spectrum of the hydrochloride of R-terbutaline prepared in Example 1.
- Figure 4 is the liquid chromatography of the hydrochloride of R-terbutaline prepared in Example 1.
- Figure 5 shows the liquid chromatogram of the existing racemic terbutaline (Hongsen Pharmaceutical).
- the specific preparation method and testing method of the present invention are conventional methods, such as testing purity and ee value by conventional liquid chromatography (HPLC+chiral column).
- HPLC+chiral column HPLC+chiral column
- the production method of the present invention can be expressed as follows.
- Example 2 On the basis of Example 1, the mixed solvent of THF (200 mL) and isopropanol (200 mL) was replaced with isopropanol (400 mL), and the rest remained unchanged, and the two-step yield of compound 6 was 60%, Further preparation of R-terbutaline hydrochloride 8 , ee 98.8%.
- the method provided by the invention uses cheap and easily available chiral tert-butyl sulfinamide as a chiral auxiliary group, controls the asymmetric reduction of ketones to a desired chiral secondary alcohol, and the chiral auxiliary group can be removed under simple acidic conditions .
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Catalysts (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Description
Claims (10)
- 根据权利要求2所述使用手性辅基制备左旋特布他林的方法,其特征在于,把S-(-)-叔丁基亚磺酰胺溶于有机溶剂中,加入碱,然后滴入叔丁基溴,0~60℃反应2~5小时,然后加入3,5-二苄氧基溴代苯乙酮,继续在30~80℃反应2~8小时,得到化合物5。
- 根据权利要求2所述使用手性辅基制备左旋特布他林的方法,其特征在于,把化合物5溶于溶剂,加入季铵盐,然后在0~10℃下加入硼氢化钠,还原反应得到化合物6。
- 根据权利要求2所述使用手性辅基制备左旋特布他林的方法,其特征在于,把化合物6溶于醇溶剂中,加入浓盐酸,0~60℃反应2~5小时,得到化合物7。
- 根据权利要求1所述使用手性辅基制备左旋特布他林的方法,其特征在于,钯催化剂为无机钯催化剂;醇溶剂为小分子醇。
- 根据权利要求6所述使用手性辅基制备左旋特布他林的方法,其特征在于,钯催化剂为钯碳催化剂;醇溶剂为甲醇。
- 根据权利要求1所述使用手性辅基制备左旋特布他林的方法,其特征在于,把化合物 7溶于醇溶剂中,加入钯催化剂,滴入盐酸,在常压氢气中氢解1~3小时,得到产物左旋特布他林。
- S-(-)-叔丁基亚磺酰胺在制备左旋特布他林中的应用。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP21938298.3A EP4332085A1 (en) | 2021-04-27 | 2021-04-27 | Method for preparing l-terbutaline by using chiral auxiliary group |
PCT/CN2021/090369 WO2022226812A1 (zh) | 2021-04-27 | 2021-04-27 | 一种使用手性辅基制备左旋特布他林的方法 |
JP2023558989A JP2024514774A (ja) | 2021-04-27 | 2021-04-27 | 不斉補助剤を使用してレボテルブタリンを調製する方法 |
US18/282,913 US20240190807A1 (en) | 2021-04-27 | 2021-04-27 | A method for preparing r-terbutaline using chiral auxiliary groups |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2021/090369 WO2022226812A1 (zh) | 2021-04-27 | 2021-04-27 | 一种使用手性辅基制备左旋特布他林的方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022226812A1 true WO2022226812A1 (zh) | 2022-11-03 |
Family
ID=83847702
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/090369 WO2022226812A1 (zh) | 2021-04-27 | 2021-04-27 | 一种使用手性辅基制备左旋特布他林的方法 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20240190807A1 (zh) |
EP (1) | EP4332085A1 (zh) |
JP (1) | JP2024514774A (zh) |
WO (1) | WO2022226812A1 (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1273966A (zh) | 1999-10-19 | 2000-11-22 | 中国科学院成都有机化学研究所 | 光学纯的肾上腺素类β-激动剂的组合拆分制备法 |
CN105330553A (zh) * | 2015-12-02 | 2016-02-17 | 湖南理工学院 | 一种采用疏水性相转移手性萃取分离特布他林对映体的方法 |
CN106631831A (zh) * | 2015-10-29 | 2017-05-10 | 北京盈科瑞药物研究院有限公司 | 一种左旋特布他林的制备方法 |
CN108129367A (zh) * | 2018-02-05 | 2018-06-08 | 南开大学 | 一种构建手性亚磺酰亚胺α位手性四级碳的构建方法及其产品与应用 |
CN110156614A (zh) | 2018-02-13 | 2019-08-23 | 东莞市凯法生物医药有限公司 | 一种左旋(-)特布他林的制备方法及其抗哮喘的应用 |
-
2021
- 2021-04-27 EP EP21938298.3A patent/EP4332085A1/en active Pending
- 2021-04-27 JP JP2023558989A patent/JP2024514774A/ja active Pending
- 2021-04-27 US US18/282,913 patent/US20240190807A1/en active Pending
- 2021-04-27 WO PCT/CN2021/090369 patent/WO2022226812A1/zh active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1273966A (zh) | 1999-10-19 | 2000-11-22 | 中国科学院成都有机化学研究所 | 光学纯的肾上腺素类β-激动剂的组合拆分制备法 |
CN106631831A (zh) * | 2015-10-29 | 2017-05-10 | 北京盈科瑞药物研究院有限公司 | 一种左旋特布他林的制备方法 |
CN105330553A (zh) * | 2015-12-02 | 2016-02-17 | 湖南理工学院 | 一种采用疏水性相转移手性萃取分离特布他林对映体的方法 |
CN108129367A (zh) * | 2018-02-05 | 2018-06-08 | 南开大学 | 一种构建手性亚磺酰亚胺α位手性四级碳的构建方法及其产品与应用 |
CN110156614A (zh) | 2018-02-13 | 2019-08-23 | 东莞市凯法生物医药有限公司 | 一种左旋(-)特布他林的制备方法及其抗哮喘的应用 |
Non-Patent Citations (6)
Title |
---|
CHEM. PHARM. BULL., vol. 65, 2017, pages 389 - 395 |
J. MED. CHEM., vol. 15, 1972, pages 1182 - 1183 |
JOURNAL OF MOLECULAR CATALYSIS B, vol. 84, 2012, pages 83 - 88 |
KYEONG H. K.HYUN J. K.SEON-PYO H.SANG D. S., ARCH. PHARM. RES., vol. 23, 2000, pages 441 - 445 |
LIAO JIAN, PENG XIAOHUA, ZHANG JUHUA, YU KAIBEI, CUI XIN, ZHU JIN, DENG JINGEN: "Facile resolution of racemic terbutaline and a study of molecular recognition through chiral supramolecules based on enantiodifferentiating self-assembly", ORG.BIOMOL.CHEM., 20 February 2003 (2003-02-20), XP055980446, Retrieved from the Internet <URL:https://pubs.rsc.org/en/content/articlepdf/2003/ob/b211327a> [retrieved on 20221111] * |
UCHIMOTO HITOMI, IKEDA MIKI, TANIDA SAORI, OHHASHI KAYO, CHIHARA YOSHIKO, SHIGETA TAKASHI, ARIMITSU KENJI, YAMASHITA MASAYUKI, NIS: "Green Synthesis of (<i>R</i>)-Terbutaline for Recyclable Catalytic Asymmetric Transfer Hydrogenation in Ionic Liquids", CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN, JP, vol. 65, no. 4, 1 January 2017 (2017-01-01), JP , pages 389 - 395, XP055980448, ISSN: 0009-2363, DOI: 10.1248/cpb.c16-00949 * |
Also Published As
Publication number | Publication date |
---|---|
US20240190807A1 (en) | 2024-06-13 |
JP2024514774A (ja) | 2024-04-03 |
EP4332085A1 (en) | 2024-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2484673B1 (en) | A process for the resolution of (R,S)-nicotine | |
KR100812046B1 (ko) | 1-(2s,3s)-2-벤즈히드릴-n-(5-삼급-부틸-2-메톡시벤질)퀴누클리딘-3-아민의 제조 방법 | |
JPH11505229A (ja) | 4−アリール−ピペリジン誘導体を製造する方法 | |
US20130096346A1 (en) | Resolution methods for isolating desired enantiomers of tapentadol intermediates and use thereof for the preparation of tapentadol | |
CN112062767A (zh) | 一种卢美哌隆的制备方法及其中间体 | |
CN106631831B (zh) | 一种左旋特布他林的制备方法 | |
WO2006074479A1 (en) | Process for preparing tolterodine tartrate | |
EP2094693B1 (en) | A method for the preparation of solifenacin | |
WO2022226812A1 (zh) | 一种使用手性辅基制备左旋特布他林的方法 | |
WO2002068376A1 (en) | Process for the preparation of rasagiline and its salts | |
CN113264839B (zh) | 一种使用手性辅基制备左旋特布他林的方法 | |
WO2014034957A1 (ja) | (r)-1,1,3-トリメチル-4-アミノインダンの製造方法 | |
US20120259121A1 (en) | Process for the preparation of montelukast and salts thereof | |
EP1074539B1 (en) | Process for producing optically active 3,3,3,-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof | |
CN111944855B (zh) | 一种合成(r)-1-(4-(苄氧基)-3-硝基苯基)-2-溴乙醇的方法 | |
MXPA02007594A (es) | Procedimiento para la separacion enzimatica de racematos de derivados de aminometil-aril-ciclohexanol. | |
MX2012009920A (es) | Proceso para la obtencion de los enantiomeros del praziquantel y sus derivados 4´-hidroxilados. | |
EP2545028A1 (en) | A novel stereospecific synthesis of (-) (2s,3s)-1-dimethylamino-3-(3-methoxyphenyl)-2-methyl pentan-3-ol | |
JP2009507783A (ja) | 高光学純度を有するキラル3−ヒドロキシピロリジン化合物及びその誘導体の製造方法 | |
WO2005121066A1 (fr) | Procede de preparation de (1r, 2s)-(x)-ephedrine ou d'un hydrochlorure de cette derniere | |
EP2099740B1 (en) | A process for the preparation of optically pure r (-) salbutamol and its pharmaceutically acceptable salts | |
JP4350530B2 (ja) | 光学活性3,3,3−トリフルオロ−2−ヒドロキシプロピオン酸誘導体の製造方法 | |
CN114409552A (zh) | 一种盐酸左旋沙丁胺醇的制备方法 | |
JP2018507178A (ja) | ジペプチジルペプチダーゼ−4(dpp−4)酵素阻害剤の調製のための新規プロセス | |
KR20230096576A (ko) | 광학활성 3-디메틸아미노-3-페닐-1-프로판올 및 이를 이용한 다폭세틴 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21938298 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18282913 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023558989 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2021938298 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021938298 Country of ref document: EP Effective date: 20231127 |